Business Wire

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

Share

Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.

Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.

“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.

Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.

Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”

The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.

“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.

About Conformation-X Therapeutics

Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.

Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.

About Pledge Therapeutics

Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.

Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643

Maria Martin
mmartin@pledge-tx.com
1-339-502-8630

Krishna Kandala
kkandala@pledge-tx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HubHead Corp. Acquires DataSeer Inc. Assets to Expand its Vertical AI Capabilities18.4.2024 23:15:00 EEST | Press release

In a strategic move to bolster its vertical AI strategy for asset-intensive industries, HubHead Corp. announced today its acquisition of the assets of DataSeer, Inc. The acquisition adds to HubHead’s portfolio of tools focused on using AI and machine learning to improve asset and maintenance master data and assisting asset-intensive businesses in digitizing data to create digital twins. HubHead’s software improves the effectiveness of our customers’ Enterprise Asset Management (EAM) and CMMS solutions. As a frontrunner in the application of AI to enhance asset and maintenance master data quality, HubHead is dedicated to collaborating with customers to provide innovative software-as-a-service (SaaS) solutions. AI makes it easier for asset-intensive businesses to ensure their maintenance and operations, and EAM solutions are more efficient, reliable, and prepared for future initiatives. Greg Dee, CEO of HubHead, emphasized the importance of AI tools to create the asset and maintenance ma

Banco Popular Launches a New Campaign 'We Follow Your Rhythm'; Introduces Audio Branding18.4.2024 21:29:00 EEST | Press release

Puerto Rico is a recognized global platform for musical talent, with a variety of rhythms and genres representing its cultural wealth. Rooted in that influence, Banco Popular announced a new campaign titled “We Follow Your Rhythm”. The Bank used the analogy of music to capture the diversity of its customers, the wide range of their banking preferences and the ways that Popular meets those banking needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418724939/en/ Tommy Torres (Photo: Business Wire) “For the past 130 years Popular has evolved with cultural, social, and economic changes to ensure it serves optimally and efficiently. We have always moved at the pace of our clients, understanding their preferences, and constantly transforming our offering to meet their needs so they can carry out their transactions in an agile and simple way,” said Ignacio Álvarez, president and CEO of Popular. “We Follow Your Rhythm” positio

B2Broker Increases Leverage on Major FX Pairs to 1:20018.4.2024 19:06:00 EEST | Press release

Leading Prime of Prime liquidity provider B2Broker is committed to quality, always listening to their clients' needs to provide them with the best possible tools to bring in more end users and gain a competitive edge in the industry. In this regard, B2Broker announces the rise of the leverage to 1:200 for major FX pairs, thereby reducing the margin requirements from 1% to 0.5%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418556608/en/ B2Broker increases leverage on major FOREX pairs to 1:200 and to 1:50 for BTC/USD and ETH/USD pairs, enhancing the market position of their clients. (Graphic: Business Wire) Additionally, with the cryptocurrency market thriving and traders’ demands for higher leverage growing, the company has increased leverage up to 1:50 for BTCUSD and ETHUSD, reducing margin requirements from 10% to 2% and significantly enhancing the clients' market position. Additional Information about B2Broker Liquid

Proemion Holding GmbH Agrees to Acquire TrendMiner NV to Expand Industrial Asset-Monitoring and Analytics Platform18.4.2024 18:32:00 EEST | Press release

Proemion Holding GmbH, a global provider of advanced data and analytics technology for mobile industrial assets, announced an agreement to acquire TrendMiner NV, an industrial analytics company, from Software AG. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417486875/en/ The spinout and acquisition of TrendMiner, based in Belgium, will significantly expand Proemion’s existing analytics capabilities for critical industrial equipment, which help equipment manufacturers and operators gather machine data remotely and continuously to maximize uptime and performance. TrendMiner produces a complementary, web-based, self-service analytics platform for monitoring critical equipment inside complex industrial environments. The technology allows teams to collaborate, learn and improve the overall performance of all production. TrendMiner’s technology is used across industries including chemicals, oil and gas, pharmaceuticals, power

Kinsted Wealth Selects Objectway for Enhanced and Fully Integrated Client and Investment Management Platform to Drive Growth18.4.2024 16:28:00 EEST | Press release

Objectway, global Top 100 FinTech provider of as-a-service software and services to banks, wealth and asset managers, has partnered with Kinsted Wealth, a Calgary (CAN) based independent wealth manager serving private individuals and institutional investors. Objectway will help Kinsted Wealth manage their business in a fully integrated and centralised manner, ultimately accelerating the growth of its discretionary business and external advisor network. This new client partnership follows the recent addition of leading digital wealth solutions provider Nest Wealth to Objectway, building on the momentum of the Group’s active expansion and operational capability in Canada. Objectway's digital front-end will deliver improved client experience for Kinsted Wealth by providing investors with omnichannel interaction, client engagement and front-office productivity, supported by an online portal and mobile apps for investors. This solution will enable Kinsted Wealth to improve client experience

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye